Vaxxas strikes deal to tee up trial of COVID-19 vaccine patch

Vaxxas has secured an exclusive license to a SARS-CoV-2 spike protein from The University of Texas at Austin, positioning it to move a needle-free, room-temperature stable COVID-19 vaccine patch into the clinic.

Massachusetts-based Vaxxas has a patch delivery technology, HD-MAP, that uses an array of projections to get vaccines to immune cells below the surface of the skin. Vaxxas uses dry-coating technology to apply vaccines onto the projections. In doing so, Vaxxas thinks it can eliminate the need to ship and store the patches in cold chain conditions, simplify delivery and potentially enable self-administration.